UBS在Abbott公司收购精密科学后保留其购买评级,增强了其癌症筛查能力。 UBS keeps its Buy rating on Abbott after its acquisition of Exact Sciences, boosting its cancer screening capabilities.

在该公司获得Exact Science之后,UBS保持其在Abbot实验室的购买评级,提高了Abbott在非侵入性癌症筛查中的立足点,尤其是通过Cologuard测试检测的直肠癌检测。 UBS maintains its Buy rating on Abbott Laboratories after the company acquired Exact Sciences, boosting Abbott’s foothold in non-invasive cancer screening, particularly colorectal cancer detection through the Cologuard test. 投资银行认为采购在战略上是稳妥的,期待从协同作用和对早期疾病检测需求的不断增加中长期回收。 The investment bank views the acquisition as strategically sound, expecting long-term accretion from synergies and rising demand for early disease detection. UBS强调Abbott的强劲现金流动、医疗设备、药品和营养的多样化经营以及创新管道是支持持续增长和股东价值的关键优势,尽管市场波动和医疗成本不断上升。 UBS highlights Abbott’s strong cash flow, diversified business across medical devices, pharmaceuticals, and nutrition, and innovation pipeline as key strengths supporting sustained growth and shareholder value despite market volatility and rising healthcare costs.